Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

They decreased the risk of psychotic disorders by 18%, Alzheimer’s disease by 12% and addiction disorders by an average of 13%. Novo Nordisk markets its blockbuster semaglutide (GLP-1 ...